Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  I am impressed with Bioscience Valuation's professional approach that enables us to plan future revenues and capacity utilization much better now.

Dr. Folker Ruchatz, SVP Contract Manufacturing Business, Boehringer Ingelheim Biopharmaceuticals GmbH

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Investment Decisions

Investment Decisions shall be driven by thorough analyses that integrate
  • all commercial aspects including a drug's current and future competitive environment as well as pharmacoeconomics (also see > Commercial Assessment),
  • the analysis and mitigation of development risk (also see > R&D Productivity Increase),
  • the identification of a company's cost of capital,
  • the calculation of risk-adjusted net present values ('NPVs'),
  • the assessment how value is expected to increase once set milestones have been reached,
  • 'comparables', i.e. market transactions with a known value.

Bioscience Valuation supports management with comprehensive analyses and clear investment recommendations that can be shared with any stakeholder.


Case:
A 'top 25' pharma company wished to improve its project prioritization metrics. Bioscience Valuation implemented its valuation methodology by educating the company's newly formed portfolio management team.

A transparent, value-driven prioritization process was tailored to the organiation involving all functions and management levels, including the CEO.